港股異動丨騰盛博藥盤初一度升超16% 治療乙肝候選藥數據良好
騰盛博藥(2137.HK)盤初拉昇一度升超16%至3.16港元。公司昨日收市後公佈,一項2期研究治療組別層面揭盲的第24和第36周頂線數據結果。該數據來自BRII-179(VBI-2601),一種首創的Pre-S1、Pre-S2和S治療性疫苗聯合治療慢性乙型肝炎患者中期分析。24周治療數據顯示,BRII-179/PEG-IFNα治療總體上安全性及耐受性良好,不良事件與此前報吿的BRII-179治療不良事件相似。目前隨訪正在進行中。公司首席醫學官David Margolis博士表示,BRII-179能誘導功能性免疫反應,對PEG-IFNα等其他治療方式起到補充作用,會繼續評估這一一流的免疫治療候選藥物,為全球2.9億慢性乙型肝炎病毒(HBV)感染者提供最高的HBV功能性治癒率。此外,公司指,新啟動一項HBV2期研究,並計劃在該2期研究中納入亞太地區曾接受過BRII-179治療的患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.